![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) Following up to 240 Weeks of Treatment in Patients with HBeAg+ and HBeAg-Chronic Hepatitis B Virus Infection
|
|
|
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
P Marcellin1, EJ Heathcote2, A Corsa3, Y Liu3,
MD Miller3, and KM Kitrinos3
1Hepatology Department, HopitalBeaujon, University of Paris, Clichy, France;
2Toronto General Hospital, University of Toronto, Ontario, Canada;
3Gilead Sciences, Inc., Foster City, CA, USA
![AASLD1.gif](../images/111411/111411-2/AASLD1.gif)
![AASLD2.gif](../images/111411/111411-2/AASLD2.gif)
![AASLD3.gif](../images/111411/111411-2/AASLD3.gif)
![AASLD4.gif](../images/111411/111411-2/AASLD4.gif)
![AASLD5.gif](../images/111411/111411-2/AASLD5.gif)
![AASLD6.gif](../images/111411/111411-2/AASLD6.gif)
![AASLD7.gif](../images/111411/111411-2/AASLD7.gif)
![AASLD8.gif](../images/111411/111411-2/AASLD8.gif)
![AASLD9.gif](../images/111411/111411-2/AASLD9.gif)
![AASLD11.gif](../images/111411/111411-2/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|